

PRESS RELEASE

DICOT

Dicot to Participate in Upcoming August Investor Conferences

Press release: Uppsala, August 21, 2019. Dicot AB (publ), developer of drugs targeting sexual dysfunction, today announced that Göran Beijer, CEO, will participate and host one-on-one investor meetings at the following upcoming investor conferences: BioStock Live Capital Markets Day and the LSX Nordic Congress 2019.

Event Details:

BioStock Live Capital Markets Day

Tuesday, August 27, 2019

Presentation at 10:00 AM CET

A live webcast of the presentation can be accessed via the following link:

<https://www.eventbrite.com/e/biostock-live-sthlm-august-27-biljetter-68783139221>

LSX Nordic Congress 2019

Thursday, August 29, 2019

Hosting Investor Meetings

Göran Beijer will be representing the company and hosting one-on-one meetings during the conference. To schedule a meeting please contact the LSX Nordic Congress organizers or Gabriela Urquilla at Gabriela.Urquilla@dicot.se.

For more information, please contact:

Julie Silber

CFO/Investor Relations Director, Dicot

Tel.: +46-79-3486277

Email: julie.silber@dicot.se

About Dicot AB (publ)

Dicot's business concept is to develop the product Libiguin™ as a drug for the treatment of sexual dysfunctions. The development takes place in-house up to clinical phases. It is the company's intention to subsequently enter into strategic alliances at appropriate times, or alternatively conduct a trade sale, with established major pharmaceutical companies to be able to introduce Libiguin™ on the world market. Dicot is listed on the Spotlight Stock Market and has approximately 700 shareholders. www.dicot.se